DealsSumma Equity takes majority stake in SengenicsSumma Equity has acquired a majority stake in Sengenics, a functional proteomics company.ByIris Dorbian14 October 2020•3 mins readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs